An Animated Whiteboard View of Newly Approved and Emerging Non-factor Replacement Therapies for the Management of Patients with Hemophilia A
Michael Callaghan, MD
Assistant Professor of Pediatrics
Hematology & Oncology
Wayne State University School of Medicine
This enduring activity is focused on the care of patients with hemophilia A.
This activity is designed to meet the educational needs of hematologists who treat patients with hemophilia A.
After completing the CME activity, learners should be better able to:
- Describe advantages and disadvantages associated with traditional management approaches for those with hemophilia A, including the potential for immunogenicity
- Review the mechanisms of action and clinical profiles of newly approved and emerging non-factor replacement therapies for patients with hemophilia A
- Discuss strategies to individualize prophylaxis using non-factor replacement therapies based on patient characteristics
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with Hemophilia A. Credits: 1.0 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Callaghan is a consultant for Roche/Genentech, Takeda, Bayer, Pfizer, Novo Nordisk, Kedrion, Grifols, Spark, Biomarin, Hema Biologics, Global Blood therapeutics, and Bioverativ/Sanofi. He is a member of Speakers Bureaus for Bayer, Takeda, Novo Nordisk, and Roche/Genentech. He has contracted research for Roche/Genentech, Pfizer, Global Blood therapeutics, Sancillio, Amgen, and Biomarin. Dr. Callaghan owns stock in Alnylum.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: July 17, 2019
EXPIRATION DATE: July 17, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.